Table 5 Cox regression analysis of factors associated with mTTSP in 65 patients who received subsequent chemotherapy in the PS group
Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
HR(95%CI) | P value | HR(95%CI) | P value | |
BRCA status (BRCA WT vs. BRCA mutation) | 0.960(0.540–1.707) | 0.889 | ||
Chemotherapy combined with bevacizumab ( Yes vs. No) | 0.766(0.444–1.321) | 0.337 | ||
chemotherapy pattern(platinum-based or not) | 0.934(0.618–1.413) | 0.748 | ||
Duration of PARPi maintenance therapy(≥ 12months or not) | 0.265(0.080–0.875) | 0.029 | 0.572(0.320–1.021) | 0.059 |